Abstract
Uncontrolled trials of strategies directed at inadequate antidepressant response are prone to falsely positive results. Most of those studies which have used placebo control have assessed augmentation and the addition of lithium to tricyclic antidepressants or serotonin reuptake inhibitors has so far received the most support. A smaller literature shows promise for augmentation with triiodothyronine, pindolol and dehydroepiandrosterone.